CRVO
CervoMed Inc. Common Stock
Nasdaq · usd
CervoMed Inc. Common Stock (CRVO) trades at $2.24 (-2.99%) as of 2:16:32 PM EDT on Oct 26, 2026, -11.02% over the past month. Market cap is $34.93M, with 7.0 days to cover in short interest.
Stock performance
How CervoMed Inc. Common Stock (CRVO) stock has performed from one day to one year, with its 52-week range.
- 1D
- -2.16%
- 1W
- -2.16%
- 1M
- -11.02%
- YTD
- -71.39%
- 1Y
- -67.81%
- 52-wk range
- $2.13 – $10.00
Key statistics
Today's trading snapshot for CRVO: day range, open, previous close, volume and market cap.
- Day range
- $2.18 – $2.29
- Open
- $2.29
- Prev close
- $2.31
- Volume
- 58.25K
- Market cap
- $34.93M
- Shares out
- 15.12M
Valuation and profitability ratios: P/E, P/S, ROE
Valuation and profitability ratios for CervoMed Inc. Common Stock: P/E, P/S, P/B, ROE and more.
- P/E
- —
- P/S
- 105.42
- P/B
- 1.52
- P/FCF
- —
- ROE
- -132.2%
- ROA
- -116.8%
- Debt/Equity
- 0.00
- Div yield
- 0.00%
As of Oct 23, 2026
8-K filings
Material corporate events CervoMed Inc. Common Stock has disclosed to the SEC on Form 8-K.
- Investor presentationOct 14, 2026
Certain information concerning the business, clinical studies, development plans, financial position, and related matters of CervoMed Inc. is being made available on our website, www.cervomed.com, under the heading, “Investors – Events and Presentations.” Representatives of the Company may use this presentation ... in connection with conferences, meetings, and presentations to investors, analysts and others.
- Clinical trial resultsOct 13, 2026
On October 12, 2026, CervoMed Inc. issued a press release announcing initial data from the first 12 weeks of the Company's Phase 2a clinical trial in nonfluent variant primary progressive aphasia ("nfvPPA"), which were presented in a late-breaking oral presentation at the 15th International Society of Frontotemporal Dementias Annual Meeting.
- Investor presentationOct 9, 2026
Certain information concerning the business, clinical studies, development plans, financial position, and related matters of CervoMed Inc. is being made available on our website, www.cervomed.com, under the heading, “Investors – Events and Presentations.” Representatives of the Company may use this presentation ... in connection with conferences, meetings, and presentations to investors, analysts and others.
- Business updateSep 28, 2026
On September 28, 2026, CervoMed Inc. (the "Company") issued a press release announcing pharmacokinetic, regulatory, and manufacturing updates related to its lead drug candidate, neflamapimod.
- Investor presentationSep 10, 2026
Certain information concerning the business, clinical studies, development plans, financial position, and related matters of CervoMed Inc. has been made available on our website, www.cervomed.com, under the heading, "Investors – Events and Presentations." Representatives of the Company may use this presentation ... in connection with conferences, meetings, and presentations to investors, analysts and others.
Dividend history and stock splits
CervoMed Inc. Common Stock's recent dividend payments and stock splits.
Dividends
No recent dividends.
Splits
- 1-for-50Apr 19, 2022
- 1-for-15Dec 14, 2018
CRVO short interest
How heavily CRVO is shorted: shares short, days to cover and average daily volume.
- Days to cover
- 7.0
- Short interest
- 1.34M
- Avg volume
- 189.96K
As of · reported to FINRA twice monthly.
CRVO news
The latest news and headlines about CervoMed Inc. Common Stock (CRVO).
- CervoMed’s neflamapimod elected for inclusion in UK EXPERTS-ALS platform designed to prioritize promising treatments for Amyotrophic Lateral SclerosispositiveGlobeNewswire Inc.· Feb 18, 2026
- CervoMed Announces Late-Breaking Data at the 18th CTAD Conference Demonstrating Neflamapimod Significantly Slows Clinical Progression in Dementia with Lewy BodiespositiveGlobeNewswire Inc.· Dec 4, 2025
- CervoMed Presents New Plasma Biomarker Data That Indicates Neflamapimod Broadly Improves Neuroinflammation and Neurodegeneration in Dementia with Lewy Bodies (DLB)positiveGlobeNewswire Inc.· Dec 2, 2025
- CervoMed to Share New Data on Neflamapimod as a Treatment for Dementia with Lewy Bodies at the 18th Clinical Trials on Alzheimer's Disease (CTAD) ConferencepositiveGlobeNewswire Inc.· Nov 24, 2025
- Presenting on Emerging Growth Conference 87 Day 2 on October 23; Register to live streamneutralGlobeNewswire Inc.· Oct 22, 2025
Frequently asked questions
What is the CervoMed Inc. Common Stock (CRVO) stock price today?
CervoMed Inc. Common Stock (CRVO) is trading at $2.24 (-2.99% on the day) as of 2:16:32 PM EDT on Oct 26, 2026. Prices are delayed at least 15 minutes; real-time quotes are available from the Massive API.
What is CervoMed Inc. Common Stock?
CervoMed Inc is a clinical-stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod, has the potential to treat and improve synaptic dysfunction, the reversible aspect of the…
What is the short interest in CRVO?
As of Sep 30, 2026, CRVO has 1.34M shares short and 7.0 days to cover.
What exchange is CRVO listed on?
CervoMed Inc. Common Stock (CRVO) trades on Nasdaq in USD, in the PHARMACEUTICAL PREPARATIONS industry.
Build with AI
Build an analysis of CRVO with your agent
Point Claude or ChatGPT at the Massive MCP server and recreate this page from live data.
Connect the Massive MCP server (API reference: massive.com/docs/llms.txt) and build a CRVO analysis: the latest quote, key ratios (P/E, P/S, ROE), short interest, recent insider activity and the latest news.
Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.